At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19

NCT04656691 · clinicaltrials.gov ↗
PHASE4
Phase
TERMINATED
Status
139
Enrollment
INDUSTRY
Sponsor class

Stopped In April 2021 FDA revoked the Emergency Use Authorization after determining that the known and potential benefits of bamlanivimab, when administered alone, no longer outweigh the known and potential risks for its authorized use.

Conditions

Interventions

Sponsor

Daniel Griffin

Collaborators